- Home
- RDIB vs STXS Comparison
RDIB vs STXS Comparison
Compare RDIB & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- STXS
- Stock Information
- Founded
- RDIB 1937
- STXS 1990
- Country
- RDIB United States
- STXS United States
- Employees
- RDIB N/A
- STXS N/A
- Industry
- RDIB Movies/Entertainment
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RDIB Consumer Discretionary
- STXS Health Care
- Exchange
- RDIB Nasdaq
- STXS Nasdaq
- Market Cap
- RDIB 279.6M
- STXS 261.1M
- IPO Year
- RDIB N/A
- STXS 2004
- Fundamental
- Price
- RDIB $12.91
- STXS $2.85
- Analyst Decision
- RDIB
- STXS
- Analyst Count
- RDIB 0
- STXS 0
- Target Price
- RDIB N/A
- STXS N/A
- AVG Volume (30 Days)
- RDIB 6.3K
- STXS 395.1K
- Earning Date
- RDIB 08-14-2025
- STXS 11-10-2025
- Dividend Yield
- RDIB N/A
- STXS N/A
- EPS Growth
- RDIB N/A
- STXS N/A
- EPS
- RDIB N/A
- STXS N/A
- Revenue
- RDIB $219,213,000.00
- STXS $31,806,000.00
- Revenue This Year
- RDIB $5.21
- STXS $30.92
- Revenue Next Year
- RDIB $11.45
- STXS $43.27
- P/E Ratio
- RDIB N/A
- STXS N/A
- Revenue Growth
- RDIB 7.59
- STXS 33.94
- 52 Week Low
- RDIB $5.78
- STXS $1.54
- 52 Week High
- RDIB $14.95
- STXS $3.05
- Technical
- Relative Strength Index (RSI)
- RDIB 55.20
- STXS 56.73
- Support Level
- RDIB $11.94
- STXS $2.81
- Resistance Level
- RDIB $12.95
- STXS $2.92
- Average True Range (ATR)
- RDIB 0.93
- STXS 0.11
- MACD
- RDIB -0.14
- STXS -0.01
- Stochastic Oscillator
- RDIB 60.98
- STXS 62.07
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.